Are you Dr. Ikoma?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 26 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Naruhiko Ikoma, MD is a general surgeon in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2015 - 2018
University of Texas Health Science Center at HoustonResidency, Surgery, 2011 - 2015
Keio Gujuku University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025- American Board of Surgery Surgery
- American Board of Surgery Complex General Surgical Oncology
- Join now to see all
Publications & Presentations
PubMed
- Total Venous Control and Vein-to-the-Right Superior Mesenteric Artery Approach in Robotic Pancreatoduodenectomy.Madeline B Torres, Jessica E Maxwell, Rebecca A Snyder, Hop S Tran Cao, Michael P Kim
Annals of Surgical Oncology. 2024-12-01 - ASO Visual Abstract: Survival Outcomes for Patients Who Have Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy.Yun Song, Yuki Hirata, Jaffer A Ajani, Mariela Blum Murphy, Jenny J Li
Annals of Surgical Oncology. 2024-12-01 - A propensity score matched cost analysis of robotic versus open hepatectomy.Ahad M Azimuddin, Yuki Hirata, Artem Boyev, Anish J Jain, Reed Ayabe
HPB. 2024-11-01
Authored Content
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
Press Mentions
Six-Time Cancer Survivor: How My Diagnoses Led Me to MD AndersonApril 7th, 2023- Robots Are Taking over Your Surgery (And You Should Be Excited)September 27th, 2023
